Question-and-Answer Session
Operator
(Operator Instructions) We will take our first question from David Clair from Piper Jaffray.
David Clair - Piper Jaffray
Its Dave Clair here with Bill Quirk, I guess the first question I have would be on the RVPs performance in the quarter. So if you can just maybe give us some color on the how that performs sequentially?
Pat Balthrop
Well, as I mentioned David, this is Pat during my remarks, the second quarter was an unusual quarter because the H1N1 outbreak and although we don’t provide line item revenue guidance, I will say that 2002 was unusual. The third quarter on the other hand looked more like a traditional third quarter; it was more a situation where customers were gearing up for anticipation of receiving samples. What we have seen since then however is that as patients started to present to the healthcare system, with flu like systems that revenue has continued to accelerate, that’s about as much detail as I can give you.
David Clair - Piper Jaffray
Okay. I appreciate that, and then just a little bit of question here on guidance. I was hoping, just kind of using the low end of the range that you provided. I mean that suggests a pretty nice sequential ramp here in the fourth quarter. Just hoping you can give us some additional color on how we’re getting there?
Harriss Currie
Sure. So first of all to get oriented year-to-date sales in third quarter are $82.5 million. So to achieve the guidance at the low end, $118 million obviously we have to deliver our fourth quarter revenue of $35.5 million. Although, we don’t provide line item revenue guidance, so I can’t go into a lot of detail. The fact is to get us there will be continued robust instrument sales.
The third quarter was a very nice quarter. The fourth quarter traditionally is a very solid quarter for a variety of reasons and based on where we are in the quarter. We expect to deliver a very nice instrument revenue number for the quarter. As I mentioned a second ago, the RVP revenue continues to accelerate and based on what’s happening in the marketplace and the number of patients presenting to the healthcare system. So we expect RVP to be tailwind as well.
Then lastly, as I mentioned during my remarks we expect revenue to return to a growth mode versus where we finished this quarter for example. So all of that adds up to us being highly confident and delivering a total revenue number that’s within the guidance range.
- To read the full transcript on Seeking Alpha, click here »
